May. 28 at 2:57 PM
After a strong start, is
$ADMA still the best bet, or is
$GRFS taking the lead? 🏆
💡 ADMA boasts robust Asceniv demand and 15.9% gains in 2025, but trades at a pricey 25.48X forward earnings.
📈 Meanwhile, GRFS, with its wider portfolio and Zacks Rank #2 (Buy), offers a cheaper 7.19X valuation and a significant EPS improvement of 296% in 2025.
Discover which stock could be your next winner 👉 https://www.zacks.com/commentary/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-body&ADID=SYND_STOCKTWITS_TWEET_2_2478303_BODY